Key result
Established and novel biomarkers in calcific aortic valve disease show promise for enhanced clinical decision making and identification of causal factors for the disease.
Biomarkers in calcific aortic valve disease show promise for improving risk stratification and clinical decision making, though current research remains less robust compared to atherosclerotic cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Biomarkers may aid risk stratification in calcific aortic valve disease; leaves open prospective validation before clinical adoption.
Small et al. (2017) conducted a review in Calcific aortic valve disease (CAVD). Biomarkers was evaluated. Established and novel biomarkers in calcific aortic valve disease show promise for enhanced clinical decision making and identification of causal factors for the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: